Lexicon Genetics Reports 2006 Fourth Quarter and Full Year ... - PR Newswire (press release)
February 21, 2007| Lexicon Genetics Reports 2006 Fourth Quarter and Full Year ... PR Newswire (press release), NY - ... small molecule compound with potential application in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. ... |
Pharmacopeia Announces Fourth Quarter and Year-End Results for 2006 - PR Newswire (press release)
February 21, 2007| Pharmacopeia Announces Fourth Quarter and Year-End Results for 2006 PR Newswire (press release), NY - PS433540, the first and only DARA compound in development, is being developed as a potential treatment for hypertension and diabetic nephropathy. ... Pharmacopeia Collaboration Advances Novel Therapeutic Candidate ... |
Drug maker produces documentary on chronic illness - International Herald Tribune
February 21, 2007 Boston Globe | Drug maker produces documentary on chronic illness International Herald Tribune, France - Instead, it focuses on several of the autoimmune diseases Remicade is approved to treat: rheumatoid arthritis, psoriasis and Crohn's disease. ... 2 new treatments for Crohn's due soon |
Lexicon Genetics Reports 2006 Fourth Quarter and Full Year ... - PharmaLive.com (press release)
February 21, 2007| Lexicon Genetics Reports 2006 Fourth Quarter and Full Year ... PharmaLive.com (press release), PA - ... small molecule compound with potential application in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. ... |
Lexicon Genetics Reports 2006 Fourth Quarter and Full Year ... - MSN Money
February 21, 2007| Lexicon Genetics Reports 2006 Fourth Quarter and Full Year ... MSN Money - ... small molecule compound with potential application in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. ... |
Investing in Stem Cell Stocks: Growth Industry of the Future? - Seeking Alpha
February 21, 2007| Investing in Stem Cell Stocks: Growth Industry of the Future? Seeking Alpha, NY - ... develops and markets autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, cardiovascular diseases, and diabetes, ... |